-DOCSTART- -X- O
BACKGROUND -X- _ O
: -X- _ O
Severe -X- _ B-Patient
Acute -X- _ I-Patient
Respiratory -X- _ I-Patient
Syndrome -X- _ I-Patient
( -X- _ I-Patient
SARS -X- _ I-Patient
) -X- _ I-Patient
and -X- _ I-Patient
Middle -X- _ I-Patient
East -X- _ I-Patient
Respiratory -X- _ I-Patient
Syndrome -X- _ I-Patient
( -X- _ I-Patient
MERS -X- _ I-Patient
) -X- _ I-Patient
are -X- _ O
two -X- _ O
coronaviruses -X- _ O
with -X- _ O
demonstrated -X- _ O
potential -X- _ O
to -X- _ O
generate -X- _ O
significant -X- _ O
nosocomial -X- _ O
outbreaks. -X- _ O
In -X- _ O
particular -X- _ O
, -X- _ O
MERS -X- _ O
continues -X- _ O
to -X- _ O
pose -X- _ O
a -X- _ O
significant -X- _ O
threat -X- _ O
in -X- _ O
the -X- _ O
Middle -X- _ O
East -X- _ O
since -X- _ O
2012. -X- _ O
Currently -X- _ O
, -X- _ O
no -X- _ O
licensed -X- _ O
vaccine -X- _ O
or -X- _ O
drug -X- _ O
treatment -X- _ O
is -X- _ O
available -X- _ O
to -X- _ O
treat -X- _ O
patients -X- _ O
infected -X- _ O
with -X- _ O
either -X- _ O
coronavirus. -X- _ O
However -X- _ O
, -X- _ O
there -X- _ O
are -X- _ O
some -X- _ O
MERS -X- _ O
vaccines -X- _ O
in -X- _ O
the -X- _ O
preclinical -X- _ O
stage -X- _ O
of -X- _ O
development. -X- _ O
We -X- _ O
sought -X- _ O
to -X- _ O
evaluate -X- _ O
the -X- _ O
potential -X- _ O
impact -X- _ O
of -X- _ O
targeted -X- _ B-Intervention
vaccination -X- _ I-Intervention
strategies -X- _ I-Intervention
for -X- _ O
mitigating -X- _ O
SARS -X- _ B-Outcome
and -X- _ I-Outcome
MERS -X- _ I-Outcome
outbreaks -X- _ I-Outcome
in -X- _ O
healthcare -X- _ O
settings -X- _ O
using -X- _ O
simple -X- _ O
mathematical -X- _ O
models -X- _ O
and -X- _ O
detailed -X- _ O
historic -X- _ O
transmission -X- _ O
trees -X- _ O
describing -X- _ O
the -X- _ O
progression -X- _ O
of -X- _ O
past -X- _ O
nosocomial -X- _ O
outbreaks -X- _ O
of -X- _ O
SARS -X- _ O
and -X- _ O
MERS. -X- _ O
RESULTS -X- _ O
: -X- _ O
Our -X- _ B-Outcome
findings -X- _ I-Outcome
suggest -X- _ I-Outcome
that -X- _ I-Outcome
vaccination -X- _ I-Outcome
strategies -X- _ I-Outcome
targeting -X- _ I-Outcome
patients -X- _ I-Outcome
and -X- _ I-Outcome
healthcare -X- _ I-Outcome
workers -X- _ I-Outcome
, -X- _ I-Outcome
which -X- _ I-Outcome
have -X- _ I-Outcome
been -X- _ I-Outcome
disproportionately -X- _ I-Outcome
affected -X- _ I-Outcome
during -X- _ I-Outcome
past -X- _ I-Outcome
outbreaks -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
assuming -X- _ I-Outcome
two -X- _ I-Outcome
vaccination -X- _ I-Outcome
coverage -X- _ I-Outcome
levels -X- _ I-Outcome
at -X- _ I-Outcome
50 -X- _ I-Outcome
and -X- _ I-Outcome
75 -X- _ I-Outcome
% -X- _ I-Outcome
have -X- _ I-Outcome
the -X- _ I-Outcome
potential -X- _ I-Outcome
to -X- _ I-Outcome
avert -X- _ I-Outcome
nearly -X- _ I-Outcome
50 -X- _ I-Outcome
% -X- _ I-Outcome
or -X- _ I-Outcome
more -X- _ I-Outcome
of -X- _ I-Outcome
MERS -X- _ I-Outcome
or -X- _ I-Outcome
SARS -X- _ I-Outcome
cases. -X- _ I-Outcome
CONCLUSION -X- _ O
: -X- _ O
Our -X- _ O
modeling -X- _ O
results -X- _ O
informed -X- _ O
by -X- _ O
historic -X- _ O
outbreak -X- _ O
data -X- _ O
for -X- _ O
SARS -X- _ O
and -X- _ O
MERS -X- _ O
suggest -X- _ O
that -X- _ O
vaccination -X- _ B-Outcome
strategies -X- _ I-Outcome
targeting -X- _ I-Outcome
patients -X- _ I-Outcome
could -X- _ I-Outcome
be -X- _ I-Outcome
an -X- _ I-Outcome
effective -X- _ I-Outcome
measure -X- _ I-Outcome
to -X- _ I-Outcome
mitigate -X- _ I-Outcome
and -X- _ I-Outcome
prevent -X- _ I-Outcome
outbreaks -X- _ I-Outcome
in -X- _ O
the -X- _ O
healthcare -X- _ O
setting. -X- _ O
ELECTRONIC -X- _ O
SUPPLEMENTARY -X- _ O
MATERIAL -X- _ O
: -X- _ O
The -X- _ O
online -X- _ O
version -X- _ O
of -X- _ O
this -X- _ O
article -X- _ O
( -X- _ O
10.1186 -X- _ O
/ -X- _ O
s12976-019-0112-6 -X- _ O
) -X- _ O
contains -X- _ O
supplementary -X- _ O
material -X- _ O
, -X- _ O
which -X- _ O
is -X- _ O
available -X- _ O
to -X- _ O
authorized -X- _ O
users -X- _ O
. -X- _ O

